Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines

Management of Immunotherapy-Related Toxicities, Version 2.2024 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Thompson, J. A., Schneider, B. J., Brahmer, J., Abu Zaid, M., Achufusi, A., Armand, P., Berkenstock, M. K., Bermas, B., Braaten, T., Budde, L. E., Chokshi, S., Crees, Z. D., Davies, M., Deng, C., Gesthalter, Y., Jain, M., Jain, P., Jallouk, A., Kaffenberger, B. H., Khalil, M., Lechner, M. G., Li, T., Marr, A., Mcgettigan, S., Mcpherson, J., Medina, T., Mohindra, N. A., Olszanski, A. J., Oluwole, O., Patel, S. P., Prosek, J., Reddy, S., Reid, P., Ryan, J., Ryder, M., Salman, H., Santomasso, B., Shofer, S., Sosman, J. A., Wang, Y., Zaha, V. G., Zucker, S., Lyons, M., Awotiwon, A., Hang, L. 2024; 22 (9): 582-592

Abstract

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell-engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.

View details for DOI 10.6004/jnccn.2024.0057

View details for Web of Science ID 001371282900010

View details for PubMedID 39536465